Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

FDA approval

Imfinzi Approved in the US in First and Only Immunotherapy Combination for Patients with BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer

May 29, 2026

NYSE: $AZN

Source: Read More

$AZN, bladder cancer, FDA Approval, Imfinzi, immunotherapy, POTOMAC Phase 3

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Get FREE Biotech Stock Catalyst Reports

Email

Notify me about related content and special offers.

Yes No

If you opt in above, we use this information to send related content, discounts, and other special offers.